Developing a Novel AAV Capsid to Enable Para-retinal Administration Across Multiple Retinal Indications
Time: 10:00 am
day: Conference Day One
Details:
- Demonstrating capsid AAV204 viability in non-human primates to establish the periretinal route of administration for retinal gene therapy
- Advancing X-linked retinoschisis program with capsid AAV204 data in mice to support progression into large animal studies
- Platforming the capsid and delivery route combination to expand therapeutic applications across multiple retinal indications including autosomal dominant optic atrophy (ADOA)
